December 2019 - Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
If you’re squeamish about needles, you’ll be delighted to know that Portal Instruments is developing technology that will allow needle-free injections of important medications through the skin. It’s especially important for people with chronic conditions that require constant injections.
Portal’s CEO and co-founder, Dr. Patrick Anquetil is DOING THIS. He’s a scientist and engineer who is also able to see the world through the lens of business, allowing him to spot opportunity in a very important industry.
It’s a great example of how business – and even profit – can drive the development of technology with the potential to help millions of people.
Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
The podcast discusses Dr. Anquetil’s journey so far, and much more, including…
– How to protect breakthrough inventions with the government’s help
– The hardest part of running a startup and how to overcome it
– Fundraising tips for getting the capital you need
– Why Dr. Anquetil’s education takes a backseat, even in this highly specialized industry
– And more
Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
March 2024 - Portal Instruments is pleased to be returning to Dana Point, California to share its drug delivery technology with investors and other emerging medtech companies at LSI USA '24. Patrick Anquetil, CEO, will be presenting the updates.
Portal Instruments, a leader in patient-centric drug delivery innovation, is pleased to announce the publication of a collaborative study in the journal Bioengineering & Translational Medicine, highlighting the viability of its next-generation, needle-free injector (NFI) fo
Please fill out the details below and we will get back to you shortly.